Ligand Pharmaceuticals Incorporated ( Nachrichten ) (NASDAQ:LGND) today announced positive results from a Phase I clinical trial with LGD-4665 in a poster titled ? Single and Multiple Oral Doses of LGD-4665, a Small Molecule Thrombopoeitin Receptor Agonist, Increase Platelet Counts in Healthy Male Subjects, ?? at the American Society of Hematology (ASH) 49 th Annual Meeting, being held at the …
Read More at FinanzNachrichten…
No related posts.